Biotech firm raises USD 80m for pharmaceutically treating hearing loss

US-based Pipeline Therapeutics has raised USD 80m to be put towards developing a pharmaceutical treatment against hearing loss.

Photo: Joachim Adrian/Politiken/Ritzau Scanpix

A series of new institutional investors are so confident about one particular drug candidate for treating hearing loss from biotech firm Pipeline Therapeutics that they, alongside existing investors, have posted USD 80m in the San Diego-based company.

Pipeline Therapeutics focuses on the development and commercialization of small molecules, which can be used for neuroregeneration, and the company is currently enrolling patients for a phase I-IIa study with leading candidate Pipe-505 for the treatment of so-called sensorineural hearing loss (SNHL), states Pipeline Therapeutics in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs